ARTICLE | Clinical News
Arcturus preclinical data
November 14, 1994 8:00 AM UTC
The Woburn, Mass., company reported animal findings with a topical mixture that optimizes skin concentration of the inhibitor of DNA synthesis, and minimizes its spread to other organs.
At the meeting of the American Association of Pharmaceutical Scientists in San Diego, the company presented data showing lower levels of the drug in blood and liver with a proprietary mixture, but equivalent delivery of methotrexate within skin, compared to another formulation. ...